Page 39 - Read Online
P. 39
through mammalian target of rapamycin signal cascade. PLoS One 19. Yasuda S, Arii S, Mori A, Isobe N, Yang W, Oe H, Fujimoto A,
2015;10:e0122373. Yonenaga Y, Sakashita H, Imamura M. Hexokinase II and VEGF
17. Bannach P, Klimek F, Mayer D. Early bioenergetic changes in expression in liver tumors: correlation with hypoxia-inducible factor 1
hepatocarcinogenesis: preneoplastic phenotypes mimic responses to alpha and its significance. J Hepatol 2004;40:117-23.
insulin and thyroid hormone. J Bioenerg Biomembr 1997;29:303-13. 20. Guzman G, Chennuri R, Chan A, Rea B, Quintana A, Patel R, Xu PZ, Xie
18. Klimek F, Bannasch P. Isoenzyme shift from glucokinase to hexokinase H, Hay N. Evidence for heightened hexokinase II immunoexpression
is not an early but a late event in hepatocarcinogenesis. Carcinogenesis in hepatocyte dysplasia and hepatocellular carcinoma. Dig Dis Sci
1993;14:1857-61. 2015;60:420-6.
30 Hepatoma Research | Volume 2 | Issue 1 | January 15, 2016